ReviewTherapeutic advances in psychopharmacology2026
A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations.
Review in Therapeutic advances in psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecules, meaning, and physiology: disentangling the active ingredients of psychedelic therapeutics.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psychedelic therapies are gaining attention as tools to alleviate anxiety and depression across various clinical populations. However, the mechanisms behind psychedelics' therapeutic efficacy and the potential differences in how patients with certain diagnoses experience their subjective effects remain unknown. One commonly suggested mediator of positive outcomes across psychedelics trials is the occurrence of mystical-type experiences. Objectives: This scoping review examines the relationship between psychedelic-induced mystical-type experiences and changes in anxiety and depression symptoms, comparing findings across populations with a life-threatening disease (LTD) and other psychiatric populations. Given the unique challenges faced by patients with an LTD diagnosis, this review aimed to determine whether there are any distinct patterns differentiating the effects of mystical-type experiences and mood outcomes in this population from other psychiatric populations. Charting methods: Following a scoping review method, PubMed, Embase, and PsycINFO were reviewed. Eligibility criteria: Clinical trials administering psychedelics to adults and measuring mystical-type experiences and their relationship to anxiety and/or depression outcomes were included. Sources of evidence: Thirteen clinical trials ( Results: Across all studies, 69% of trials reported a positive relationship between mystical-type experiences and improvement in anxiety and/or depression outcomes. This relationship was found in 80% of LTD studies and 63% of studies in depressive populations. Conclusion: Mystical-type experiences were commonly associated with reductions in anxiety and/or depression symptoms following psychedelic therapy in both LTD and depressive populations. However, this relationship may depend on multiple factors, including the timing of symptom assessments and therapeutic context. Future studies should examine the variables that affect mystical-type experiences, along with other aspects of set and setting, to determine how to best facilitate positive outcomes induced by psychedelics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.